T cell

Mustang Bio Announces Publication in Nature Medicine of Data from Phase 1 Trial Evaluating MB-101 IL13Rα2-targeted CAR T-Cells in High-Grade Glioma

Retrieved on: 
Thursday, March 7, 2024

WORCESTER, Mass., March 07, 2024 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for difficult-to-treat cancers and rare genetic diseases, today announced Phase 1 clinical data were published in Nature Medicine that demonstrated the promising safety and clinical activity of Mustang’s MB-101 (IL13Ra2-targeted CAR T-cells) for the treatment of patients with recurrent and refractory malignant glioma, including glioblastoma.

Key Points: 
  • MB-101 was developed by City of Hope, one of the largest cancer research and treatment organizations in the United States, and exclusively licensed to Mustang.
  • Central nervous system (CNS) increases in inflammatory cytokines, including IFNγ, CXCL9, and CXCL10, were associated with CAR T-cell administration and bioactivity.
  • Primary endpoints were safety and feasibility, with secondary endpoints measuring therapy-related cytokine dynamics, CAR T-cell persistence and clinical outcomes.
  • Dr. Brown has a financial interest in Mustang and has previously been a paid consultant for the company.

San Francisco Witnesses the Voice of GCT Titans GenScript Biotech Global Forum Outlines the Future of the Industry

Retrieved on: 
Friday, January 12, 2024

On January 10 this year, GenScript Biotech hosted the "Satellite Session" of the J.P. Morgan annual conference—the 2024 GenScript Biotech Global Forum in San Francisco.

Key Points: 
  • On January 10 this year, GenScript Biotech hosted the "Satellite Session" of the J.P. Morgan annual conference—the 2024 GenScript Biotech Global Forum in San Francisco.
  • GenScript Biotech is committed to building a high-quality platform for exchange and cooperation for global peers, driving the advancement of the cell and gene industry.
  • since the first global forum was held in 2020, GenScript Biotech has created numerous valuable opportunities for industry peers.
  • This grand event brought together the wisdom and strength of global elites in the biopharmaceutical industry, sparking a profound discourse on the future of GCT.

Boehringer Ingelheim and 3T Biosciences enter into a second partnership to develop next-generation cancer immunotherapies

Retrieved on: 
Thursday, January 4, 2024

INGELHEIM, Germany and SOUTH SAN FRANCISCO, Calif., Jan. 4, 2024 /PRNewswire/ -- Boehringer Ingelheim and 3T Biosciences ("3T") today announced they have entered into a new strategic collaboration and licensing agreement focused on discovering and developing next-generation life-changing cancer immunotherapies.

Key Points: 
  • INGELHEIM, Germany and SOUTH SAN FRANCISCO, Calif., Jan. 4, 2024 /PRNewswire/ -- Boehringer Ingelheim and 3T Biosciences ("3T") today announced they have entered into a new strategic collaboration and licensing agreement focused on discovering and developing next-generation life-changing cancer immunotherapies.
  • Despite the significant transformation of the cancer treatment landscape by immunotherapies, sustained remission only occurs in 15-20% of all cases of cancer.
  • This second research partnership with 3T builds on the successful completion of the initial research partnership announced last year by the two companies.
  • Boehringer Ingelheim is eligible to receive royalties on future product sales by 3T Biosciences arising from the agreement.

Human medicines European public assessment report (EPAR): Teriflunomide Mylan, teriflunomide, Date of authorisation: 09/11/2022, Revision: 1, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024

Human medicines European public assessment report (EPAR): Teriflunomide Mylan, teriflunomide, Date of authorisation: 09/11/2022, Revision: 1, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Teriflunomide Mylan, teriflunomide, Date of authorisation: 09/11/2022, Revision: 1, Status: Authorised

Provectus Biopharmaceuticals Announces Notice of Allowance of First U.S. Patent of Rose Bengal Sodium for Use as Anticancer and Antiviral Vaccine Adjuvant

Retrieved on: 
Monday, December 18, 2023

The allowed application would be Provectus’s first patent award in the field of vaccines from the USPTO.

Key Points: 
  • The allowed application would be Provectus’s first patent award in the field of vaccines from the USPTO.
  • Innovate Calgary, the innovation company of the University of Calgary in Alberta, Canada, is a co-assignee.
  • The research underlying the allowed application was led by Dr. Narendran and his lab team (the Narendran Lab).
  • This work also portends the potential benefit of PV-10 in combination with targeted immunotherapies and antibody-drug conjugates for cancer treatment.

Replay and its engineered NK cell therapy company Syena announce exclusive licensing agreement with National Institutes of Health for TCRs targeting cancer neoantigens

Retrieved on: 
Monday, December 18, 2023

These will be developed by Replay’s oncology-focused product company, Syena, to expand its pipeline of engineered T-Cell Receptor-Natural Killer (TCR-NK) cell therapies.

Key Points: 
  • These will be developed by Replay’s oncology-focused product company, Syena, to expand its pipeline of engineered T-Cell Receptor-Natural Killer (TCR-NK) cell therapies.
  • The TCRs, targeting validated cancer neoantigens KRAS, p53, HPV16 and MAGE, were discovered by Steven Rosenberg, M.D., Ph.D., Chief of the Surgery Branch at the NIH National Cancer Institute’s (NCI) Center for Cancer Research and a pioneer of immunotherapies and gene therapies for advanced cancers.
  • Preclinical development of the new TCR-NK programs will advance alongside the clinical development of Syena’s lead engineered TCR-NK cell therapy candidate targeting NY-ESO-1, and the PRAME program announced today.
  • Adrian Woolfson, Executive Chairman, President, and Co-Founder of Replay, said: “The TCRs licensed from NIH address several cancer neoantigens of medical importance and will significantly expand our first-in-class, engineered TCR-NK therapy operations.

Lucius Partners Portfolio Company Voltron Therapeutics, Inc. Announces Completion of a Trial Protocol to Study its Self Assembling Vaccine to Target Prostate Stem Cell Antigen

Retrieved on: 
Monday, November 20, 2023

NEW YORK, Nov. 20, 2023 /PRNewswire/ -- Voltron Therapeutics, Inc., a Lucius Partners portfolio company, today announced that it has finalized the protocol for a Dose-Ranging Efficacy Study of VTX-0P4, a protein-based cancer vaccine targeting Prostate Stem Cell Antigen (PSCA).

Key Points: 
  • NEW YORK, Nov. 20, 2023 /PRNewswire/ -- Voltron Therapeutics, Inc., a Lucius Partners portfolio company, today announced that it has finalized the protocol for a Dose-Ranging Efficacy Study of VTX-0P4, a protein-based cancer vaccine targeting Prostate Stem Cell Antigen (PSCA).
  • Voltron recently demonstrated immunogenicity against PSCA in a double blind pre-clinical trial conducted at the Vaccine and Immunotherapy Center at the Massachusetts General Hospital.
  • In that trial VTX-0P4 significantly augmented T-Cell responses when compared to controls against this important tumor target while, once again, exhibiting a very clean safety profile.
  • "We are excited to initiate Voltron's PSCA pre-clinical efficacy trial," said James Ahern, Managing Partner of Laidlaw & Company and co-founder of Lucius Partners.

MedGenome achieves 10x Genomics Certified Service provider qualification for single cell sequencing

Retrieved on: 
Tuesday, November 7, 2023

FOSTER CITY, Calif., Nov. 7, 2023 /PRNewswire/ -- MedGenome , a global precision medicine company specializing in omics solutions, announced today that it has achieved the 10x Genomics Certified Service Provider qualification for its single cell offering.

Key Points: 
  • FOSTER CITY, Calif., Nov. 7, 2023 /PRNewswire/ -- MedGenome , a global precision medicine company specializing in omics solutions, announced today that it has achieved the 10x Genomics Certified Service Provider qualification for its single cell offering.
  • Combining MedGenome's expertise in single cell data analysis promises to deliver groundbreaking insights into complex and rare diseases.
  • The 10x Genomics certification highlights MedGenome's expertise in offering single-cell sequencing tools to help researchers accelerate their genomic studies.
  • MedGenome is positioned as the top genomics research service provider in the San Francisco Bay Area.

King Faisal Specialist Hospital & Research Centre Successfully Concludes its Role as a Strategic Healthcare Partner at Global Health Exhibition 2023

Retrieved on: 
Monday, November 6, 2023

RIYADH, Saudi Arabia, Nov. 06, 2023 (GLOBE NEWSWIRE) -- The Global Health Exhibition, held from October 29 to October 31, 2023, proved an outstanding success for the King Faisal Specialist Hospital & Research Centre (KFSH&RC).

Key Points: 
  • RIYADH, Saudi Arabia, Nov. 06, 2023 (GLOBE NEWSWIRE) -- The Global Health Exhibition, held from October 29 to October 31, 2023, proved an outstanding success for the King Faisal Specialist Hospital & Research Centre (KFSH&RC).
  • “KFSH&RC's transformative journey into a non-profit institution, primarily focusing on serving patients from the Gulf region, began in 2021.
  • The Global Health Exhibition has been a remarkable platform to explore new opportunities that will further bolster the healthcare landscape in the Kingdom and beyond."
  • The hospital also received the prestigious "Best Public Services Call Centre of The Year – Critical" award at the Annual Middle East Call Centre 2023 Awards.

Provectus Biopharmaceuticals Announces Presentation of Preclinical PV-10 Vaccine Adjuvant Data at Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting

Retrieved on: 
Monday, November 6, 2023

This research has been led by Aru Narendran, MD, PhD and his lab team from the Cumming School of Medicine at the University of Calgary in Alberta, Canada.

Key Points: 
  • This research has been led by Aru Narendran, MD, PhD and his lab team from the Cumming School of Medicine at the University of Calgary in Alberta, Canada.
  • Dr. Narendran and his colleagues previously discovered that PV-10 activated stimulator of interferon (IFN) genes (STING), demonstrating its potential as a vaccine adjuvant in PV-10-mediated systemic anti-tumor immune responses.
  • See Thakur et al., American Association for Cancer Research 2020 Virtual Annual Meeting II .
  • In its SITC work, the Narendran lab showed that PV-10 treatment induced STING activation, upregulated cytokines and chemokines, and increased IFN-γ secretion by CD8+ T-cells.